GlassScriptPhysician profile
Amir Cohen
NPI 1841487220
$265,677.55
in general payments reported to CMS, 2019-2025
22 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $20K · 2021: $57K · 2022: $86K · 2023: $24K · 2024: $23K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $9,855 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,900 · Travel and Lodging: $3,080 · Consulting Fee: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,450.00 |
| Food and Beverage | $9,855.46 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,900.00 |
| Travel and Lodging | $3,080.45 |
| Consulting Fee | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $86,544.05 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $63,835.00 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Bausch & Lomb Americas INC. | $44,051.74 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Stellaris Elite |
| Allergan, INC. | $42,419.98 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $12,741.11 | 2020-2021 | |
| Glaukos Corporation | $11,845.07 | 2019-2024 | Idose, Photrexa Cross-Linking Kit |
| Alcon Vision LLC | $2,076.79 | 2020-2025 | Lensx, Rocklatan, Clareon |
| New World Medical,INC. | $419.63 | 2020-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Ocular Therapeutix, INC. | $417.41 | 2021-2025 | Dextenza |
| Biotissue Holdings INC. | $359.14 | 2022-2025 | |
| Astellas Pharma US INC | $350.01 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.23 | 2019-2021 | |
| Thea Pharma INC. | $169.22 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $129.70 | 2024-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $41.28 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $18.00 | 2025 | Tyrvaya |
| Dompe US, INC. | $14.66 | 2022 | |
| Omeros Corporation | $14.41 | 2021 | |
| Genentech USA, INC. | $13.80 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.68 | 2019 | |
| Eyepoint US, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.